CDAK

Codiak BioSciences, Inc. [CDAK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CDAK Stock Summary

In the News

12:17 29 Mar 2024 CDAK

Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?

Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences started the marketing process before entering into Chapter 11.

07:26 29 Mar 2024 CDAK

Codiak BioSciences files for bankruptcy, looks to sell off assets

Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” the Massachusetts-based biopharmaceutical company said in a statement.

06:48 29 Mar 2024 CDAK

Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 29 Mar 2024 CDAK

Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages

– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –

06:48 29 Mar 2024 CDAK

Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

09:52 29 Mar 2024 CDAK

Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity

Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.  In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.

07:34 29 Mar 2024 CDAK

Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11:17 29 Mar 2024 CDAK

Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

06:10 29 Mar 2024 CDAK

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

06:48 29 Mar 2024 CDAK

Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CDAK Financial details

Company Rating
Neutral
Market Cap
2.83M
Income
-29.24M
Revenue
33.57M
Book val./share
1.55
Cash/share
2.06
Dividend
-
Dividend %
-
Employees
102
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
-0.05
Forward P/E
-
PEG
0.01
P/S
0.11
P/B
0.04
P/C
0.03
P/FCF
-0.06
Quick Ratio
3.58
Current Ratio
4.24
Debt / Equity
1.57
LT Debt / Equity
1.5
-
-
EPS (TTM)
-1.22
EPS next Y
-
EPS next Q
-
EPS this Y
-86.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-99.79%
EPS Q/Q
134.48%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
32.77%
Inst Trans
0.57%
ROA
-23%
ROE
-72%
ROC
-0.31%
Gross Margin
100%
Oper. Margin
-142%
Profit Margin
-122%
Payout
-
Shs Outstand
49.63M
Shs Float
19.63M
-
-
-
-
Target Price
-
52W Range
0.017-4.25
52W High
-
52W Low
-
RSI
54
Rel Volume
8.09
Avg Volume
1.6M
Volume
12.93M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
3.93495
-
-
Volatility
0.01%, 0.01%
Prev Close
0%
Price
0.057
Change
-48.18%

CDAK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K
Revenue per share
00.030.461.05
Net income per share
-3.4-6.03-14.04-1.91
Operating cash flow per share
-2.33-0.13-10.01-3.4
Free cash flow per share
-2.97-0.93-13.33-3.55
Cash per share
6.786.3514.043.53
Book value per share
7.021.672.32.45
Tangible book value per share
7.021.672.32.45
Share holders equity per share
7.021.672.32.45
Interest debt per share
00.7510.253.01
Market cap
158.9M159.17M204.55M242.79M
Enterprise value
140.81M158.42M178.62M228.83M
P/E ratio
-3.57-2.01-2.3-5.83
Price to sales ratio
0410.2370.1710.59
POCF ratio
-5.2-93.46-3.23-3.27
PFCF ratio
-4.09-13.07-2.42-3.14
P/B Ratio
1.737.2514.044.54
PTB ratio
1.737.2514.044.54
EV to sales
0408.3161.289.98
Enterprise value over EBITDA
-3.29-2.12-1.99-3.73
EV to operating cash flow
-4.61-93.03-2.82-3.09
EV to free cash flow
-3.62-13.01-2.12-2.96
Earnings yield
-0.28-0.5-0.43-0.17
Free cash flow yield
-0.24-0.08-0.41-0.32
Debt to equity
00.444.321.18
Debt to assets
00.080.420.37
Net debt to EBITDA
0.420.010.290.23
Current ratio
18.64.765.313.32
Interest coverage
0-267.17-47.7-25.8
Income quality
0.690.020.692
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
054.226.811.2
Research and developement to revenue
0153.3525.382.83
Intangibles to total assets
0000
Capex to operating cash flow
0.276.150.330.04
Capex to revenue
0-27-7.22-0.14
Capex to depreciation
-4.82-3.78-3.8-0.51
Stock based compensation to revenue
018.672.430.44
Graham number
23.1615.0726.9610.27
ROIC
-0.53-2.58-0.76-0.51
Return on tangible assets
-0.46-0.68-0.59-0.24
Graham Net
6.35-0.39-7.56-1.88
Working capital
86.16M74.36M76.11M63.01M
Tangible asset value
92.03M21.95M14.57M53.51M
Net current asset value
85.43M107K-43.02M-27.99M
Invested capital
00.444.321.18
Average receivables
02.96M2.96M644.5K
Average payables
01.5M2.2M1.93M
Average inventory
01.12M1.12M-644.5K
Days sales outstanding
05.56K020.51
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
00.07017.79
Payables turnover
0000
Inventory turnover
0000
ROE
-0.48-3.61-6.1-0.78
Capex per share
-0.63-0.8-3.32-0.15

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.050.340.570.580
Net income per share
-0.970.1-0.35-0.29-0.68
Operating cash flow per share
-0.69-0.96-0.93-0.65-0.4
Free cash flow per share
-0.71-0.98-0.94-0.66-0.4
Cash per share
4.423.442.521.862.06
Book value per share
1.522.392.161.971.55
Tangible book value per share
1.522.392.161.971.55
Share holders equity per share
1.522.392.161.971.55
Interest debt per share
2.831.52.812.782.47
Market cap
364.57M249.24M140.68M64.78M19.67M
Enterprise value
328.44M209.85M146.61M84.85M29.19M
P/E ratio
-4.227.53-4.51-2.48-0.29
Price to sales ratio
315.132.3811.074.93702.68
POCF ratio
-23.83-11.58-6.75-4.44-1.95
PFCF ratio
-23-11.4-6.69-4.39-1.94
P/B Ratio
10.724.662.911.460.51
PTB ratio
10.724.662.911.460.51
EV to sales
283.8727.2611.546.451.04K
Enterprise value over EBITDA
-17.01-22.74-24.31-15.73-1.86
EV to operating cash flow
-21.46-9.75-7.03-5.81-2.89
EV to free cash flow
-20.72-9.6-6.97-5.75-2.88
Earnings yield
-0.060.01-0.06-0.1-0.87
Free cash flow yield
-0.04-0.09-0.15-0.23-0.51
Debt to equity
1.840.71.291.391.57
Debt to assets
0.390.220.420.470.46
Net debt to EBITDA
1.874.27-0.98-3.72-0.61
Current ratio
4.53.326.064.664.24
Interest coverage
-31.24.08-13.75-10.81-28.23
Income quality
0.714.182.62.150.52
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.211.80.530.56234.39
Research and developement to revenue
13.374.271.120.97387.39
Intangibles to total assets
00000
Capex to operating cash flow
0.040.020.010.010
Capex to revenue
-0.47-0.04-0.01-0.01-0.32
Capex to depreciation
-0.32-0.85-0.13-0.23-0.01
Stock based compensation to revenue
2.670.270.180.281.68
Graham number
5.772.334.113.594.87
ROIC
-0.160.06-0.05-0.05-0.14
Return on tangible assets
-0.140.01-0.05-0.05-0.13
Graham Net
-1.17-1.84-2.01-2.07-1.74
Working capital
80.81M63.01M58.37M44M46.78M
Tangible asset value
34.01M53.51M48.38M44.4M38.93M
Net current asset value
-20.81M-27.99M-31.78M-32.3M-34.23M
Invested capital
1.840.71.291.391.57
Average receivables
00000
Average payables
1.89M1.92M1.68M1.32M1.54M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.640.04-0.16-0.15-0.44
Capex per share
-0.02-0.01-0.01-0.010

CDAK Frequently Asked Questions

What is Codiak BioSciences, Inc. stock symbol ?

Codiak BioSciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CDAK

What is Codiak BioSciences, Inc. stock quote today ?

Codiak BioSciences, Inc. stock price is $0.057 today.

Is Codiak BioSciences, Inc. stock public?

Yes, Codiak BioSciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap